long intergenic non-protein coding RNA 662Genealiases: []
Q-omics provides the consensus-scored LINC00662 profile across patient tissues and cancer cell-line models. LINC00662 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, LINC00662 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, LINC00662 RNA expression shows 20,781 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, THCA, and ACC as cancer lineages where LINC00662 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00662 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00662 survival associations across molecular data types. LINC00662 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00662 RNA expression–survival associations across cancer types. High LINC00662 expression shows unfavorable associations in KICH, ACC, LIHC, UCEC and LGG, but favorable associations in UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for LINC00662 RNA expression.
This table summarizes LINC00662 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00662. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00662 shows lower tumor expression in THCA and higher tumor expression in LIHC, LUSC, LUAD, CHOL and HNSC. The THCA box plot shows higher LINC00662 RNA expression in normal versus tumor tissue (log2 FC = −0.670, t-test p < 0.001).
This table shows molecular features associated with LINC00662 in patient tissues and cancer cell lines. In patient samples, LINC00662 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
